IP Library Granted Patent US 11,318,192
Granted Patent B2
US 11,318,192 · App. 16/963,920 · Granted May 3, 2022

Engineered proteins and methods of use

Inventors: Lisa Herron-Olson (St. Paul, MN); Patricia Tam (St. Paul, MN); Drew M. Catron (St. Paul, MN); Daryll A. Emery (Willmar, MN)
Assignee: Epitopix, LLC
A61K39/0258A61K39/39
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,318,192
App. No.
16/963,920
Granted
May 3, 2022
Kind
B2
Abstract

Provided herein are proteins that include at least one B cell domain and at least one T cell domain. Also provided are compositions that include one or more of the proteins and methods for using the proteins.

Claims (11)

1. A non-natural protein comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6.

2. A non-natural protein comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4.

3. The protein of claim 2 wherein the protein further comprises two or more copies of the amino acid sequence, wherein the two or more copies are present as a tandem repeat.

4. The protein of claim 2 wherein the protein comprises at least three copies of the amino acid sequence, wherein the three or more copies are present as a tandem repeat.

5. A non-natural protein comprising amino acids 7-518 of the amino acid sequence of SEQ ID NO:8 or amino acids 7-365 of the amino acid sequence of SEQ ID NO:10.

6. A composition comprising the protein of claim 1 .

7. The composition of claim 6 further comprising a pharmaceutically acceptable carrier.

8. The composition of claim 6 further comprising an adjuvant.

9. A composition comprising the protein of claim 2 .

10. The composition of claim 9 further comprising a pharmaceutically acceptable carrier.

11. The composition of claim 9 further comprising an adjuvant.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2024
From: EPITOPIX, LLC
To: VAXXINOVA US, INC.
Reel/Frame 066488/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: CATRON, DREW M.; TAM, PATRICIA; HERRON-OLSON, LISA
To: SYNTIRON, LLC
Reel/Frame 054351/0308 →
Continuity (2)
Provisional Application 62621796 · Jan 25, 2018
Related Publication 20210213125A1 · Jul 15, 2021